应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
YMAB Y-mAbs Therapeutics, Inc.
休市中 07-11 16:00:00 EDT
4.36
-0.16
-3.54%
盘后
4.31
-0.05
-1.15%
18:27 EDT
最高
4.48
最低
4.27
成交量
11.11万
今开
4.46
昨收
4.52
日振幅
4.76%
总市值
1.97亿
流通市值
1.09亿
总股本
4,530万
成交额
48.29万
换手率
0.44%
流通股本
2,501万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Y-Mabs Therapeutics, Inc.2025财年第一财季实现净利润-5.20百万美元,同比增加21.57%
市场透视 · 05-18
Y-Mabs Therapeutics, Inc.2025财年第一财季实现净利润-5.20百万美元,同比增加21.57%
Y-Mabs Therapeutics, Inc.盘中异动 临近收盘股价大涨5.49%
市场透视 · 05-15
Y-Mabs Therapeutics, Inc.盘中异动 临近收盘股价大涨5.49%
Truist Securities:维持Y-mAbs Therapeutics(YMAB.US)评级,由买入调整至买入评级, 目标价由18.00美元调整至14.00美元。
金融界 · 05-14
Truist Securities:维持Y-mAbs Therapeutics(YMAB.US)评级,由买入调整至买入评级, 目标价由18.00美元调整至14.00美元。
Y-Mabs Therapeutics, Inc.盘中异动 股价大跌5.30%
市场透视 · 05-14
Y-Mabs Therapeutics, Inc.盘中异动 股价大跌5.30%
奥本海默:维持Y-mAbs Therapeutics评级,由优于大市调整至优于大市评级, 目标价由21.00美元调整至20.00美元。
金融界 · 05-14
奥本海默:维持Y-mAbs Therapeutics评级,由优于大市调整至优于大市评级, 目标价由21.00美元调整至20.00美元。
Y-mAbs Therapeutics(YMAB.US):2025年Q1财报实现营收2090.4万美元,前值为1993.1万美元,预期值为1961万美元;每股收益为-0.12美元,前值为-0.15美元,预期值为-0.20美元。
金融界 · 05-13
Y-mAbs Therapeutics(YMAB.US):2025年Q1财报实现营收2090.4万美元,前值为1993.1万美元,预期值为1961万美元;每股收益为-0.12美元,前值为-0.15美元,预期值为-0.20美元。
Y-Mabs Therapeutics, Inc.盘中异动 快速拉升6.43%
市场透视 · 05-12
Y-Mabs Therapeutics, Inc.盘中异动 快速拉升6.43%
Y-Mabs Therapeutics, Inc.盘中异动 早盘股价大涨5.11%报4.32美元
市场透视 · 05-02
Y-Mabs Therapeutics, Inc.盘中异动 早盘股价大涨5.11%报4.32美元
Y-Mabs Therapeutics, Inc.盘中异动 股价大跌8.26%报4.42美元
市场透视 · 04-22
Y-Mabs Therapeutics, Inc.盘中异动 股价大跌8.26%报4.42美元
Y-Mabs Therapeutics, Inc.盘中异动 早盘股价大涨5.07%报5.18美元
市场透视 · 04-15
Y-Mabs Therapeutics, Inc.盘中异动 早盘股价大涨5.07%报5.18美元
Y-Mabs Therapeutics, Inc.盘中异动 股价大跌8.33%报4.73美元
市场透视 · 03-10
Y-Mabs Therapeutics, Inc.盘中异动 股价大跌8.33%报4.73美元
Y-Mabs Therapeutics, Inc.2024财年实现净利润-29.67百万美元,同比减少38.45%
市场透视 · 03-08
Y-Mabs Therapeutics, Inc.2024财年实现净利润-29.67百万美元,同比减少38.45%
Y-Mabs Therapeutics, Inc.盘中异动 快速拉升5.36%
市场透视 · 03-06
Y-Mabs Therapeutics, Inc.盘中异动 快速拉升5.36%
B of A Securities:维持Y-mAbs Therapeutics(YMAB.US)评级,由中性调整至中性评级, 目标价由14.00美元调整至12.00美元。
金融界 · 03-05
B of A Securities:维持Y-mAbs Therapeutics(YMAB.US)评级,由中性调整至中性评级, 目标价由14.00美元调整至12.00美元。
Truist Securities:维持Y-mAbs Therapeutics(YMAB.US)评级,由买入调整至买入评级, 目标价由21.00美元调整至18.00美元。
金融界 · 03-05
Truist Securities:维持Y-mAbs Therapeutics(YMAB.US)评级,由买入调整至买入评级, 目标价由21.00美元调整至18.00美元。
Y-Mabs Therapeutics, Inc.盘中异动 股价大跌5.46%
市场透视 · 03-05
Y-Mabs Therapeutics, Inc.盘中异动 股价大跌5.46%
Y-Mabs Therapeutics, Inc.盘中异动 早盘股价大跌15.61%
市场透视 · 03-04
Y-Mabs Therapeutics, Inc.盘中异动 早盘股价大跌15.61%
Y-mAbs Therapeutics(YMAB.US):2024年Q4财报实现营收2649.5万美元,前值为2336.3万美元,预期值为2670万美元;每股收益为-0.15美元,前值为-0.02美元,预期值为-0.13美元。
金融界 · 03-04
Y-mAbs Therapeutics(YMAB.US):2024年Q4财报实现营收2649.5万美元,前值为2336.3万美元,预期值为2670万美元;每股收益为-0.15美元,前值为-0.02美元,预期值为-0.13美元。
Y-mAbs Therapeutics 2024年第四季度GAAP每股收益$(0.15)低于预测$(0.12),销售额$26.50M低于预测$27.29M
财报速递 · 03-04
Y-mAbs Therapeutics 2024年第四季度GAAP每股收益$(0.15)低于预测$(0.12),销售额$26.50M低于预测$27.29M
Y-Mabs Therapeutics, Inc.盘中异动 快速跳水5.05%
市场透视 · 02-21
Y-Mabs Therapeutics, Inc.盘中异动 快速跳水5.05%
加载更多
公司概况
公司名称:
Y-mAbs Therapeutics, Inc.
所属市场:
NASDAQ
上市日期:
--
主营业务:
Y-mAbs Therapeutics, Inc.于2015年4月30日根据特拉华州法律注册成立。该公司是一家商业化阶段的生物制药公司,专注于新型放射免疫疗法和基于抗体的治疗产品的开发和商业化,用于治疗癌症。该公司正在利用专有的放射免疫疗法和抗体平台和专业知识来开发广泛的创新药物组合。
发行价格:
--
{"stockData":{"symbol":"YMAB","market":"US","secType":"STK","nameCN":"Y-mAbs Therapeutics, Inc.","latestPrice":4.36,"timestamp":1752264000000,"preClose":4.52,"halted":0,"volume":111077,"hourTrading":{"tag":"盘后","latestPrice":4.31,"preClose":4.36,"latestTime":"18:27 EDT","volume":2563,"amount":11142.069,"timestamp":1752272875391},"delay":0,"floatShares":25010308,"shares":45295794,"eps":-0.632943,"marketStatus":"休市中","change":-0.16,"latestTime":"07-11 16:00:00 EDT","open":4.46,"high":4.48,"low":4.265,"amount":482893.41730579996,"amplitude":0.047566,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.632943,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1752480000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1537502400000,"exchange":"NASDAQ","adjPreClose":4.52,"preHourTrading":{"tag":"盘前","latestPrice":4.55,"preClose":4.52,"latestTime":"09:24 EDT","volume":3,"amount":13.649999999999999,"timestamp":1752240290650},"postHourTrading":{"tag":"盘后","latestPrice":4.31,"preClose":4.36,"latestTime":"18:27 EDT","volume":2563,"amount":11142.069,"timestamp":1752272875391},"volumeRatio":0.8392785092022953,"impliedVol":2.0372,"impliedVolPercentile":0.816},"requestUrl":"/m/hq/s/YMAB","defaultTab":"news","newsList":[{"id":"2536594381","title":"Y-Mabs Therapeutics, Inc.2025财年第一财季实现净利润-5.20百万美元,同比增加21.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2536594381","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2536594381?lang=zh_cn&edition=full","pubTime":"2025-05-19 00:01","pubTimestamp":1747584085,"startTime":"0","endTime":"0","summary":"5月19日,Y-Mabs Therapeutics, Inc.公布财报,公告显示公司2025财年第一财季净利润为-5.20百万美元,同比增加21.57%;其中营业收入为20.90百万美元,同比增加4.87%,每股基本收益为-0.12美元。从资产负债表来看,Y-Mabs Therapeutics, Inc.总负债23.16百万美元,其中短期债务455000.00美元,资产负债比为0.05,流动比率为4.78。机构评级:截至2025年5月19日,当前有12家机构对Y-Mabs Therapeutics, Inc.目标价做出预测,其中目标均价为15.50美元,其中最低目标价为3.00美元,最高目标价为26.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000506a6e3a840&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250519000506a6e3a840&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["YMAB","LENZ"],"gpt_icon":0},{"id":"2535877091","title":"Y-Mabs Therapeutics, Inc.盘中异动 临近收盘股价大涨5.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2535877091","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535877091?lang=zh_cn&edition=full","pubTime":"2025-05-16 03:35","pubTimestamp":1747337701,"startTime":"0","endTime":"0","summary":"北京时间2025年05月16日03时35分,Y-Mabs Therapeutics, Inc.股票出现波动,股价急速上涨5.49%。Y-Mabs Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为2.06%。Y-Mabs Therapeutics, Inc.公司简介:Y-mAbs Therapeutics Inc 是一家商业化阶段的生物制药公司。消息层面,截至03时35分,《Truist Securities:维持Y-mAbs Therapeutics评级,由买入调整至买入评级, 目标价由18.00美元调整至14.00美元。》资讯为影响Y-Mabs Therapeutics, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250516033501a6e0b6ab&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250516033501a6e0b6ab&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","BK4539","BK4139","YMAB"],"gpt_icon":0},{"id":"2535706310","title":"Truist Securities:维持Y-mAbs Therapeutics(YMAB.US)评级,由买入调整至买入评级, 目标价由18.00美元调整至14.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2535706310","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535706310?lang=zh_cn&edition=full","pubTime":"2025-05-15 00:23","pubTimestamp":1747239789,"startTime":"0","endTime":"0","summary":"Truist Securities:维持Y-mAbs Therapeutics(YMAB.US)评级,由买入调整至买入评级, 目标价由18.00美元调整至14.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/15002350395046.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","YMAB"],"gpt_icon":0},{"id":"2535507174","title":"Y-Mabs Therapeutics, Inc.盘中异动 股价大跌5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2535507174","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535507174?lang=zh_cn&edition=full","pubTime":"2025-05-14 23:11","pubTimestamp":1747235506,"startTime":"0","endTime":"0","summary":"北京时间2025年05月14日23时11分,Y-Mabs Therapeutics, Inc.股票出现波动,股价大幅下跌5.30%。Y-Mabs Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.73%。Y-Mabs Therapeutics, Inc.公司简介:Y-mAbs Therapeutics Inc 是一家商业化阶段的生物制药公司。消息层面,截至23时11分,《奥本海默:维持Y-mAbs Therapeutics评级,由优于大市调整至优于大市评级, 目标价由21.00美元调整至20.00美元。》资讯为影响Y-Mabs Therapeutics, Inc.的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250514231146aa2c8eb1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250514231146aa2c8eb1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4539","BK4139","YMAB","BK4007","LENZ"],"gpt_icon":0},{"id":"2535240079","title":"奥本海默:维持Y-mAbs Therapeutics评级,由优于大市调整至优于大市评级, 目标价由21.00美元调整至20.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2535240079","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535240079?lang=zh_cn&edition=full","pubTime":"2025-05-14 22:45","pubTimestamp":1747233956,"startTime":"0","endTime":"0","summary":"奥本海默:维持Y-mAbs Therapeutics(YMAB.US)评级,由优于大市调整至优于大市评级, 目标价由21.00美元调整至20.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250514225317975995de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250514225317975995de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["YMAB","LENZ"],"gpt_icon":0},{"id":"2535728419","title":"Y-mAbs Therapeutics(YMAB.US):2025年Q1财报实现营收2090.4万美元,前值为1993.1万美元,预期值为1961万美元;每股收益为-0.12美元,前值为-0.15美元,预期值为-0.20美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2535728419","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2535728419?lang=zh_cn&edition=full","pubTime":"2025-05-13 18:43","pubTimestamp":1747132981,"startTime":"0","endTime":"0","summary":"Y-mAbs Therapeutics(YMAB.US):2025年Q1财报实现营收2090.4万美元,前值为1993.1万美元,预期值为1961万美元;每股收益为-0.12美元,前值为-0.15美元,预期值为-0.20美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/13184350352051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","YMAB"],"gpt_icon":0},{"id":"2534662276","title":"Y-Mabs Therapeutics, Inc.盘中异动 快速拉升6.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2534662276","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2534662276?lang=zh_cn&edition=full","pubTime":"2025-05-12 21:40","pubTimestamp":1747057233,"startTime":"0","endTime":"0","summary":"北京时间2025年05月12日21时40分,Y-Mabs Therapeutics, Inc.股票出现异动,股价大幅拉升6.43%。Y-Mabs Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为2.71%。其相关个股中,Cytomx Therapeutics, Inc.、Psyence Biomedical Ltd C/Wts 25/01/2029、艾吉纳斯涨幅较大,Nucana Plc、Cytomx Therapeutics, Inc.、Biodexa Pharmaceuticals Plc较为活跃,换手率分别为361.19%、75.36%、59.59%,振幅较大的相关个股有Cytomx Therapeutics, Inc.、艾吉纳斯、奥麦罗制药,振幅分别为49.55%、29.55%、23.46%。Y-Mabs Therapeutics, Inc.公司简介:Y-mAbs Therapeutics Inc 是一家商业化阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512214033aa2c8b3a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250512214033aa2c8b3a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4539","LENZ","BK4007","YMAB"],"gpt_icon":0},{"id":"2532840035","title":"Y-Mabs Therapeutics, Inc.盘中异动 早盘股价大涨5.11%报4.32美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532840035","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2532840035?lang=zh_cn&edition=full","pubTime":"2025-05-02 22:26","pubTimestamp":1746195985,"startTime":"0","endTime":"0","summary":"北京时间2025年05月02日22时26分,Y-Mabs Therapeutics, Inc.股票出现波动,股价大幅上涨5.11%。Y-Mabs Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.80%。其相关个股中,Impact Biomedical, Inc.、Adaptive Biotechnologies Corporation、Hepion Pharmaceuticals, Inc.涨幅较大,Impact Biomedical, Inc.、Pmgc Holdings Inc.、Adial Pharmaceuticals, Inc较为活跃,换手率分别为574.16%、548.03%、191.62%,振幅较大的相关个股有Impact Biomedical, Inc.、Coeptis Therapeutics Holdings Inc C/Wts 28/10/2027 、Lexaria Bioscience Corp C/Wts 14/01/2026 ,振幅分别为112.75%、71.36%、56.05%。Y-Mabs Therapeutics, Inc.公司简介:Y-mAbs Therapeutics Inc 是一家商业化阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502222625a6d126be&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250502222625a6d126be&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["YMAB","LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"2529589637","title":"Y-Mabs Therapeutics, Inc.盘中异动 股价大跌8.26%报4.42美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529589637","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529589637?lang=zh_cn&edition=full","pubTime":"2025-04-22 21:32","pubTimestamp":1745328728,"startTime":"0","endTime":"0","summary":"北京时间2025年04月22日21时32分,Y-Mabs Therapeutics, Inc.股票出现异动,股价大幅下跌8.26%。截至发稿,该股报4.42美元/股,成交量1.0645万股,换手率0.02%,振幅4.05%。Y-Mabs Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.97%。其相关个股中,阿诺医药、60 Degrees Pharmaceuticals, Inc.、Ibio, Inc.涨幅较大,Ocean Biomedical, Inc.、Lipella Pharmaceuticals Inc.、Ibio, Inc.较为活跃,换手率分别为160.60%、94.76%、34.57%,振幅较大的相关个股有Vincerx Pharma, Inc.、Revelation Biosciences, Inc.、60 Degrees Pharmaceuticals, Inc.,振幅分别为18.75%、9.55%、9.15%。Y-Mabs Therapeutics, Inc.公司简介:Y-mAbs Therapeutics Inc 是一家商业化阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422213208a46289b8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250422213208a46289b8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","BK4139","YMAB"],"gpt_icon":0},{"id":"2527443784","title":"Y-Mabs Therapeutics, Inc.盘中异动 早盘股价大涨5.07%报5.18美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527443784","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2527443784?lang=zh_cn&edition=full","pubTime":"2025-04-15 21:57","pubTimestamp":1744725476,"startTime":"0","endTime":"0","summary":"北京时间2025年04月15日21时57分,Y-Mabs Therapeutics, Inc.股票出现波动,股价急速拉升5.07%。截至发稿,该股报5.18美元/股,成交量9769股,换手率0.02%,振幅4.96%。Y-Mabs Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.18%。其相关个股中,Skye Bioscience, Inc.、Mural Oncology Plc、Verve Therapeutics, Inc.涨幅较大,Mural Oncology Plc、Metavia Inc.、Plus Therapeutics, Inc.较为活跃,换手率分别为647.79%、218.46%、87.45%,振幅较大的相关个股有Skye Bioscience, Inc.、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 、Mural Oncology Plc,振幅分别为161.07%、80.08%、66.02%。Y-Mabs Therapeutics, Inc.公司简介:Y-mAbs Therapeutics Inc 是一家商业化阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415215756aa2c6fd6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250415215756aa2c6fd6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","LENZ","YMAB"],"gpt_icon":0},{"id":"2518997222","title":"Y-Mabs Therapeutics, Inc.盘中异动 股价大跌8.33%报4.73美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518997222","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518997222?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:33","pubTimestamp":1741613588,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时33分,Y-Mabs Therapeutics, Inc.股票出现波动,股价大幅跳水8.33%。截至发稿,该股报4.73美元/股,成交量3.3021万股,换手率0.07%,振幅94.67%。Y-Mabs Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.08%。其相关个股中,Checkpoint Therapeutics, Inc.、Trevi Therapeutics, Inc.、Scisparc Ltd.涨幅较大,Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃,换手率分别为2057.25%、403.96%、61.18%,振幅较大的相关个股有Akero Therapeutics, Inc.、Xencor, Inc.、Seer, Inc.,振幅分别为99.91%、99.13%、98.72%。Y-Mabs Therapeutics, Inc.公司简介:Y-mAbs Therapeutics Inc 是一家商业化阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021330998a29d33&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031021330998a29d33&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","YMAB"],"gpt_icon":0},{"id":"2518542572","title":"Y-Mabs Therapeutics, Inc.2024财年实现净利润-29.67百万美元,同比减少38.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518542572","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518542572?lang=zh_cn&edition=full","pubTime":"2025-03-09 00:01","pubTimestamp":1741449698,"startTime":"0","endTime":"0","summary":"3月9日,Y-Mabs Therapeutics, Inc.公布财报,公告显示公司2024财年净利润为-29.67百万美元,同比减少38.45%;其中营业收入为87.69百万美元,同比增加3.38%,每股基本收益为-0.67美元。从资产负债表来看,Y-Mabs Therapeutics, Inc.总负债27.90百万美元,其中短期债务630000.00美元,资产负债比为0.05,流动比率为4.16。机构评级:截至2025年3月9日,当前有12家机构对Y-Mabs Therapeutics, Inc.目标价做出预测,其中目标均价为17.58美元,其中最低目标价为7.00美元,最高目标价为26.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000324abef9952&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309000324abef9952&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","YMAB"],"gpt_icon":0},{"id":"2517164614","title":"Y-Mabs Therapeutics, Inc.盘中异动 快速拉升5.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517164614","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517164614?lang=zh_cn&edition=full","pubTime":"2025-03-06 23:32","pubTimestamp":1741275121,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日23时32分,Y-Mabs Therapeutics, Inc.股票出现波动,股价快速上涨5.36%。Y-Mabs Therapeutics, Inc.股票所在的生物技术行业中,整体跌幅为0.60%。其相关个股中,Aeon Biopharma, Inc.、Cardio Diagnostics Holdings Inc C/Wts To Pur Com、Plus Therapeutics, Inc.涨幅较大,Aeon Biopharma, Inc.、Plus Therapeutics, Inc.、Aditxt, Inc.较为活跃,换手率分别为1870.78%、1574.08%、81.30%,振幅较大的相关个股有Cardio Diagnostics Holdings Inc C/Wts To Pur Com、Aeon Biopharma, Inc.、Moolec Science Sa C/Wts ,振幅分别为68.33%、67.37%、44.44%。Y-Mabs Therapeutics, Inc.公司简介:Y-mAbs Therapeutics Inc 是一家商业化阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306233202989ec0ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306233202989ec0ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","YMAB"],"gpt_icon":0},{"id":"2517940148","title":"B of A Securities:维持Y-mAbs Therapeutics(YMAB.US)评级,由中性调整至中性评级, 目标价由14.00美元调整至12.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517940148","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517940148?lang=zh_cn&edition=full","pubTime":"2025-03-06 02:12","pubTimestamp":1741198339,"startTime":"0","endTime":"0","summary":"B of A Securities:维持Y-mAbs Therapeutics(YMAB.US)评级,由中性调整至中性评级, 目标价由14.00美元调整至12.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06021248550882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["YMAB","LENZ"],"gpt_icon":0},{"id":"2517098947","title":"Truist Securities:维持Y-mAbs Therapeutics(YMAB.US)评级,由买入调整至买入评级, 目标价由21.00美元调整至18.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517098947","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517098947?lang=zh_cn&edition=full","pubTime":"2025-03-06 01:54","pubTimestamp":1741197251,"startTime":"0","endTime":"0","summary":"Truist Securities:维持Y-mAbs Therapeutics(YMAB.US)评级,由买入调整至买入评级, 目标价由21.00美元调整至18.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06015448550811.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["YMAB","LENZ"],"gpt_icon":0},{"id":"2517948632","title":"Y-Mabs Therapeutics, Inc.盘中异动 股价大跌5.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517948632","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517948632?lang=zh_cn&edition=full","pubTime":"2025-03-05 22:35","pubTimestamp":1741185301,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时35分,Y-Mabs Therapeutics, Inc.股票出现波动,股价快速下挫5.46%。截至发稿,该股报4.69美元/股,成交量1.0427万股,换手率0.02%,振幅0.50%。Y-Mabs Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.58%。其相关个股中,Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Silexion Therapeutics Corp涨幅较大,Silexion Therapeutics Corp、Tc Biopharm Plc、Zyversa Therapeutics, Inc.较为活跃,换手率分别为379.24%、260.81%、187.99%,振幅较大的相关个股有Aditxt, Inc.、Silexion Therapeutics Corp、Invivyd, Inc.,振幅分别为23.90%、19.80%、13.32%。Y-Mabs Therapeutics, Inc.公司简介:Y-mAbs Therapeutics Inc 是一家商业化阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223501989d46ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305223501989d46ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["YMAB","LENZ","BK4139"],"gpt_icon":0},{"id":"2516670885","title":"Y-Mabs Therapeutics, Inc.盘中异动 早盘股价大跌15.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516670885","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516670885?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:30","pubTimestamp":1741098625,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时30分,Y-Mabs Therapeutics, Inc.股票出现波动,股价大幅跳水15.61%。截至发稿,该股报4.38美元/股,成交量1.8519万股,换手率0.04%,振幅0.00%。Y-Mabs Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.00%。其相关个股中,Exicure, Inc.、Indaptus Therapeutics, Inc.、Scpharmaceuticals Inc.涨幅较大,Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃,换手率分别为1046.43%、1017.30%、402.04%,振幅较大的相关个股有Chemomab Therapeutics Ltd、Acelyrin, Inc.、Zentalis Pharmaceuticals, Inc.,振幅分别为4.64%、3.72%、2.60%。Y-Mabs Therapeutics, Inc.公司简介:Y-mAbs Therapeutics Inc 是一家商业化阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223026a25f0381&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223026a25f0381&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","YMAB","LENZ"],"gpt_icon":0},{"id":"2516279627","title":"Y-mAbs Therapeutics(YMAB.US):2024年Q4财报实现营收2649.5万美元,前值为2336.3万美元,预期值为2670万美元;每股收益为-0.15美元,前值为-0.02美元,预期值为-0.13美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516279627","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516279627?lang=zh_cn&edition=full","pubTime":"2025-03-04 19:42","pubTimestamp":1741088523,"startTime":"0","endTime":"0","summary":"Y-mAbs Therapeutics(YMAB.US):2024年Q4财报实现营收2649.5万美元,前值为2336.3万美元,预期值为2670万美元;每股收益为-0.15美元,前值为-0.02美元,预期值为-0.13美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/04194248519469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","YMAB"],"gpt_icon":0},{"id":"1106085781","title":"Y-mAbs Therapeutics 2024年第四季度GAAP每股收益$(0.15)低于预测$(0.12),销售额$26.50M低于预测$27.29M","url":"https://stock-news.laohu8.com/highlight/detail?id=1106085781","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106085781?lang=zh_cn&edition=full","pubTime":"2025-03-04 19:41","pubTimestamp":1741088469,"startTime":"0","endTime":"0","summary":"Y-mAbs Therapeutics报告每股亏损$,低于分析师共识预期亏损$ 25%。与去年同期亏损$每股相比,这一亏损增加了650%。公司报告季度销售额为$26.50百万,低于分析师共识预期的$27.29百万,差幅为2.91%。以上内容来自Benzinga Earnings专栏,原文如下:Y-mAbs $Therapeutics$ reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 25 percent. This is a 650 percent decrease over losses of $ per share from the same period last year. The company reported quarterly sales of $26.50 million which missed the analyst consensus estimate of $27.29 million by 2.91 percent. ","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["YMAB","LENZ"],"gpt_icon":0},{"id":"2513821127","title":"Y-Mabs Therapeutics, Inc.盘中异动 快速跳水5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513821127","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513821127?lang=zh_cn&edition=full","pubTime":"2025-02-22 03:44","pubTimestamp":1740167094,"startTime":"0","endTime":"0","summary":"北京时间2025年02月22日03时44分,Y-Mabs Therapeutics, Inc.股票出现异动,股价急速下跌5.05%。截至发稿,该股报5.74美元/股,成交量14.001万股,换手率0.31%,振幅7.19%。Y-Mabs Therapeutics, Inc.股票所在的生物技术行业中,整体涨幅为0.51%。其相关个股中,Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Invivyd, Inc.、Osr Holdings Inc C/Wts 09/02/2028 涨幅较大,Aditxt, Inc.、Nkgen Biotech, Inc.、Osr Holdings, Inc.较为活跃,换手率分别为311.83%、249.98%、137.95%,振幅较大的相关个股有Osr Holdings, Inc.、Invivyd, Inc.、Conduit Pharmaceuticals Inc C/Wts 22/09/2028,振幅分别为76.52%、70.25%、61.26%。Y-Mabs Therapeutics, Inc.公司简介:Y-mAbs Therapeutics Inc 是一家商业化阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222034455962bbe4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250222034455962bbe4e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["YMAB","LENZ","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ymabs.com","stockEarnings":[{"period":"1week","weight":0.014},{"period":"1month","weight":-0.1156},{"period":"3month","weight":-0.0973},{"period":"6month","weight":-0.3672},{"period":"1year","weight":-0.6388},{"period":"ytd","weight":-0.4432}],"compareEarnings":[{"period":"1week","weight":-0.0028},{"period":"1month","weight":0.037},{"period":"3month","weight":0.168},{"period":"6month","weight":0.0743},{"period":"1year","weight":0.1207},{"period":"ytd","weight":0.0641}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Y-mAbs Therapeutics, Inc.于2015年4月30日根据特拉华州法律注册成立。该公司是一家商业化阶段的生物制药公司,专注于新型放射免疫疗法和基于抗体的治疗产品的开发和商业化,用于治疗癌症。该公司正在利用专有的放射免疫疗法和抗体平台和专业知识来开发广泛的创新药物组合。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.012002},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.03065},{"month":3,"riseRate":0.428571,"avgChangeRate":0.050071},{"month":4,"riseRate":0.285714,"avgChangeRate":-0.006181},{"month":5,"riseRate":0.714286,"avgChangeRate":0.132788},{"month":6,"riseRate":0.428571,"avgChangeRate":0.032536},{"month":7,"riseRate":0.285714,"avgChangeRate":-0.045539},{"month":8,"riseRate":0.666667,"avgChangeRate":0.061965},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.051525},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.081791},{"month":11,"riseRate":0.714286,"avgChangeRate":0.029491},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.069815}],"exchange":"NASDAQ","name":"Y-mAbs Therapeutics, Inc.","nameEN":"Y-mAbs Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Y-mAbs Therapeutics, Inc.(YMAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Y-mAbs Therapeutics, Inc.(YMAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Y-mAbs Therapeutics, Inc.,YMAB,Y-mAbs Therapeutics, Inc.股票,Y-mAbs Therapeutics, Inc.股票老虎,Y-mAbs Therapeutics, Inc.股票老虎国际,Y-mAbs Therapeutics, Inc.行情,Y-mAbs Therapeutics, Inc.股票行情,Y-mAbs Therapeutics, Inc.股价,Y-mAbs Therapeutics, Inc.股市,Y-mAbs Therapeutics, Inc.股票价格,Y-mAbs Therapeutics, Inc.股票交易,Y-mAbs Therapeutics, Inc.股票购买,Y-mAbs Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Y-mAbs Therapeutics, Inc.(YMAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Y-mAbs Therapeutics, Inc.(YMAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}